Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16 and 21%, respectively had an FLT3 and NPM1 mutation. An FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score, the molecular information provided additional prognostic definition in 11% of patients.

Original publication

DOI

10.1038/leu.2014.90

Type

Journal article

Journal

Leukemia

Publication Date

10/2014

Volume

28

Pages

1953 - 1959

Keywords

Aged, Female, Genotype, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Recurrence, Remission Induction, Risk, Treatment Outcome, United Kingdom, fms-Like Tyrosine Kinase 3